Speaker Interview With Frank Borriello For 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

Speaker Interview With Frank Borriello For 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

Philadelphia, USA July 31, 2019 – MarketsandMarkets recently interviewed Frank Borriello, CEO, Alloplex Biotherapeutics, regarding the 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress, taking place on September 19 – 20, 2019 at Hilton Garden Inn Philadelphia Center City. Q. What are the recent advances in the immune-oncology and current challenges that need immediate attention? A. While there have been many advances in the field of cellular therapy in oncology, the common element limiting their adoption will be reproducibility of manufacturing, whether autologous or allogeneic, as well as generalizability across multiple tumor types, whether…

Read More

Speaker Interview With Alfred Budillon FOR 4th Annual MarketsandMarkets Epigenetics Congress

Speaker Interview With Alfred Budillon FOR 4th Annual MarketsandMarkets Epigenetics Congress

London, UK July 30, 2019 – MarketsandMarkets recently interviewed Alfred Budillon, Chief Experimental Pharmacology Unit Department, Istituto Nazionale Tumori, Italy regarding the 4th Annual MarketsandMarkets Epigenetics Congress, taking place on 3-4 October 2019 at Radisson Blu Edwardian, Grafton, London, UK. Dr. Budillon graduated in Medicine and passed the Specialty Certification in Oncology at University Federico II, Naples, Italy. He obtained the PhD in Oncology from University G. D’Annunzio of Chieti, Italy, and a master’s degree in health economy, Management and Bioethics. Dr. Budillon is currently the chief of Experimental Pharmacology, National Cancer Institute…

Read More

Speaker Interview With Gavin Reynolds For 4TH Annual MarketsandMarkets Epigenetics Congress

Speaker Interview With Gavin Reynolds For 4TH Annual MarketsandMarkets  Epigenetics Congress

London, UK July 29, 2019 – MarketsandMarkets recently interviewed Gavin Reynolds, Professor Emeritus, Queen’s University Belfast, UK regarding the 4th Annual MarketsandMarkets Epigenetics Congress, taking place on 3-4 October 2019 at Radisson Blu Edwardian, Grafton, London, UK. Gavin Reynolds is Honorary Professor at Sheffield Hallam University and Professor Emeritus, previously Chair of Neuroscience, at Queen’s University Belfast. His main research interests lie in two directions: the neurotransmitter pathology of schizophrenia, and the mechanisms underlying the beneficial and adverse effects of antipsychotics and other psychoactive drugs, with a recent focus on pharmacogenetic and…

Read More

Gene Therapy for Spinal Muscular Atrophy approved by FDA

Gene Therapy for Spinal Muscular Atrophy approved by FDA

A new treatment for a rare childhood disorder which cost $2.125 million for a single dose, one of the most expensive medicine available is approved by The US Food and Drug Administration. Spinal Muscular Atrophy, a condition driven by defects in the SMN1 gene causing burdened babies lose muscle control, the medicine is designed to treat the disease. In the US each year about 400 babies is being affected by the illness and kills those with the most common type of the disease in a couple of years. The gene…

Read More

Speaker Interview with Silvia Cainarca for the 5th Annual Neuroscience R&D Technologies Conference

Speaker Interview with Silvia Cainarca for the 5th Annual Neuroscience R&D Technologies Conference

London, UK July 24, 2019 – MarketsandMarkets recently interviewed Dr. Silvia Cainarca, Principal Investigator, iPSC Lab iTools & Solutions regarding the 5th Annual Neuroscience R&D Technologies Conference, taking place on 3-4 October 2019 at Radisson Blu Edwardian, Grafton, London, UK. Q. What are the recent advances in Neuroscience R&D Technologies for Neurodegenerative disorders and current challenges that need immediate attention? A. Even if many powerful experimental animal models were set up in these years that can recapitulate the hallmark characteristics of different neuropathic diseases, one of the main challenges in their applicability…

Read More

Speaker Interview with Lorenzo Pasquali for 4th Annual MarketsandMarkets Epigenetics Congress

Speaker Interview with Lorenzo Pasquali for 4th Annual MarketsandMarkets Epigenetics Congress

London, UK July 23, 2019 – MarketsandMarkets recently interviewed Lorenzo Pasquali, Group Leader, Endocrine Regulatory Genomics Laboratory IGTP, Spain regarding the 4th Annual MarketsandMarkets Epigenetics Congress, taking place on 3-4 October 2019 at Radisson Blu Edwardian, Grafton, London, UK. Dr. Lorenzo Pasquali is Group Leader of the Endocrine Regulatory Genomics laboratory at IGTP, Barcelona, Spain . His studies helped to map the epigenetic landscape of the insulin producing pancreatic islet cells resulting in milestone publications that opened the path to understand genomic regulation of the islets of Langerhans and shed…

Read More

AveXis Directs to Catalent’s Paragon for Extra Gene Therapy Producing Capacity

AveXis Directs to Catalent’s Paragon for Extra Gene Therapy Producing Capacity

Catalent has approved AveXis that, a Novartis Company to use its brand-new commercial manufacturing center near Baltimore-Washington International Airport as an extra site production site for its spinal muscular atrophy (SMA) gene therapy Zolgensma® (onasemnogene abeparvovec-xioi). A collaboration contract was signed by Catalent and AveXis to ensure long term strategic agreement but has not been disclosed yet. AveXis will use the dedicated production space within Paragon’s Harmans, MD, facility, a 151,000-square-foot old warehouse that Paragon changed into a contract developing and a manufacturing site which opened in April. Andy Stober,…

Read More

Genmab Partners Raised $503M U.S. IPO on Cancer Antibodies with BliNK Biomedical

Genmab Partners Raised $503M U.S. IPO on Cancer Antibodies with BliNK Biomedical

Genmab through collaboration with Blink biomedicals raised a whopping $503 Million through an American initial public offering (IPO) all this got revealed on Friday during an event. Genmab also launched an up to $200 million-per-product cancer therapy with Blink biomedicals. Blink biomedicals got a license approved by Genmab exclusively for antibodies targeting CD47, which Genmab plans to combine with its duo body platform technology to produce new bispecific antibodies for fighting cancer. Genmab CEO Jan van de Winkel, Ph.D. gave his words about this CD47 stating that “CD47 has shown…

Read More

A Study Identifies Autoimmune Disease to be Linked with Testicular Cancer

A Study Identifies Autoimmune Disease to be Linked with Testicular Cancer

Washington D.C. [USA]: According to the Scientists, an autoimmune disease looks to be linked with testicular cancer that affects men. Known to us as ‘testicular cancer-associated paraneoplastic encephalitis’, it is the reason behind any serious neurological symptoms found in men. They lose control of the limbs, speech and eye movements progressively. The autoimmune disease starts with a testicular tumor, which seems to be the reason behind the immune system attacking the brain. Affected men find themselves undiagnosed or misdiagnosed often and relevant treatment is delayed. In a study that was published in…

Read More

Passage Bio on Producing Gene Therapies with Catalent’s Paragon

Passage Bio on Producing Gene Therapies with Catalent’s Paragon

About five months ago Passage Bio that basically produces gene therapies for not so common monogenic CNS disease, in partnership with Catalent’s paragon launched a unit that is devoted to manufacturing suite Paragon Harman’s, MD, facility. The other cGMP suite whose worth is not being revealed yet is expected to hit it’s functional phase from mid-2020 and is support Passage Bio’s supply requirements from clinical through commercial phases. Stephen Squinto, P.hd, co-founder and Interim CEO at Passage Bio stated that “Passage will work contractually with Paragon to conduct GMP manufacturing…

Read More